Deerfield Management

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Meditrina, Inc. is a medical device company based in San Jose, California, established in 2016. The company specializes in developing innovative tissue removal solutions specifically designed for intrauterine pathology. Its flagship product, the Aveta System, serves healthcare professionals by providing an all-in-one solution for hysteroscopic diagnostic and therapeutic procedures, such as the removal of polyps and fibroids. The Aveta System is notable for its compact design, which allows for seamless integration into various clinical settings, including offices and operating rooms. It features advanced capabilities such as wide-angle HD hysteroscopy, improved fluid management for better pressure control, and a small insertion diameter coupled with a large working channel, all of which contribute to optimized tissue resection and enhanced procedural efficiency.

ARTMS is a technology developer focused on transforming the production of diagnostic imaging isotopes. The company specializes in the QUANTM Irradiation System, which supports decentralized and local production of essential medical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. By utilizing hospital-based medical cyclotrons, ARTMS enables cost-effective and high-yield production of these critical isotopes, allowing the nuclear medicine industry to better control and meet its supply chain requirements. Through its innovative approach, ARTMS aims to enhance the availability and accessibility of important diagnostic tools in healthcare.

LetsGetChecked is an at-home health testing platform that connects users with regulated laboratories for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Headquartered in New York, the company operates nationwide in the U.S., Canada, and Europe.

Element Science is a medical device and digital health company that develops wearable technologies to address sudden cardiac death risk in high-risk cardiovascular patients. The company designs a wearable cardioverter defibrillator and a digital platform that combines patient-centric human factors, machine learning, and rigorous electromechanical medical device development standards. Its solutions support patients transitioning from hospital to home, providing continuous protection during daily activities such as showering and sleeping. Founded in 2011 and headquartered in San Francisco, Element Science aims to reduce avoidable mortality from heart disease through integrated sensing, analytics, and lifesaving therapy delivered via wearable technology.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

ReMed provides rehabilitation services, neurobehavioral services, and supported living for people with mild, moderate, and severe brain injuries. They offer residential, outpatient, and home and community-based treatment.

Concert Genetics simplifies genetic testing processes in the U.S. healthcare system. It connects stakeholders via software tools that facilitate test selection, ordering, payment, and management. The company serves hospitals, health plans, laboratories, clinicians, patients, and regulatory agencies.

Phoenix, LLC, established in 2005 and headquartered in Madison, Wisconsin, specializes in designing and manufacturing high-yield neutron generators and other commercial nuclear technologies. These products cater to diverse applications across industries such as aerospace, defense, medical, and semiconductor, including neutron radiography, cargo screening, medical isotope production, and nuclear fuel scanning. The company's commitment to practical nuclear technologies has also set a long-term goal of contributing to clean, fusion energy production.

Adeptus Health is a healthcare organization focused on providing accessible emergency medical care through its network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent freestanding emergency facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by emergency-trained physicians and registered nurses. Additionally, Adeptus Health collaborates with University of Colorado Health to operate UCHealth Emergency Rooms in Colorado and partners with Dignity Health to manage Dignity Health Arizona General Hospital and other freestanding emergency rooms in Arizona. In Louisiana, the organization works with Ochsner Health System to enhance emergency care services. Through these initiatives, Adeptus Health aims to improve patient access to emergency medical services while minimizing wait times.

Adeptus Health is a healthcare organization focused on providing accessible emergency medical care through its network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent freestanding emergency facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by emergency-trained physicians and registered nurses. Additionally, Adeptus Health collaborates with University of Colorado Health to operate UCHealth Emergency Rooms in Colorado and partners with Dignity Health to manage Dignity Health Arizona General Hospital and other freestanding emergency rooms in Arizona. In Louisiana, the organization works with Ochsner Health System to enhance emergency care services. Through these initiatives, Adeptus Health aims to improve patient access to emergency medical services while minimizing wait times.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.

SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

iCAD specializes in cancer detection and therapy solutions. It offers AI-driven software for digital breast tomosynthesis and breast density analysis, along with tools supporting disease detection and analysis.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised. The company develops small-molecule medicines designed to increase muscle function and contractility and pursues muscle-directed investigational therapies for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy and chronic obstructive pulmonary disease.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.